BR9913742A - Inibidores de fator viia - Google Patents

Inibidores de fator viia

Info

Publication number
BR9913742A
BR9913742A BR9913742-9A BR9913742A BR9913742A BR 9913742 A BR9913742 A BR 9913742A BR 9913742 A BR9913742 A BR 9913742A BR 9913742 A BR9913742 A BR 9913742A
Authority
BR
Brazil
Prior art keywords
factor viia
viia inhibitors
inhibitors
fviia
preparation
Prior art date
Application number
BR9913742-9A
Other languages
English (en)
Inventor
Pavel Safar
Alena Safarova
Peter Wildgoose
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9913742A publication Critical patent/BR9913742A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"INIBIDORES DE FATOR VIIa"<D>. A presente invenção refere-se a novos compostos, sua preparação, seu uso e composições farmacêuticas contendo os compostos que têm um efeito antitrombótico forte através da inibição reversível do fator VIIa (FVIIa) de coagulação do sangue ativado.
BR9913742-9A 1998-09-15 1999-09-02 Inibidores de fator viia BR9913742A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98117506A EP0987274A1 (en) 1998-09-15 1998-09-15 Factor VIIa Inhibitors
PCT/EP1999/006449 WO2000015658A1 (en) 1998-09-15 1999-09-02 FACTOR VIIa INHIBITORS

Publications (1)

Publication Number Publication Date
BR9913742A true BR9913742A (pt) 2001-06-05

Family

ID=8232644

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913742-9A BR9913742A (pt) 1998-09-15 1999-09-02 Inibidores de fator viia

Country Status (25)

Country Link
US (1) US6287794B1 (pt)
EP (2) EP0987274A1 (pt)
JP (1) JP4537581B2 (pt)
KR (1) KR100665490B1 (pt)
CN (1) CN1203087C (pt)
AR (1) AR027814A1 (pt)
AT (1) ATE460424T1 (pt)
AU (1) AU760580B2 (pt)
BR (1) BR9913742A (pt)
CA (1) CA2344048A1 (pt)
CZ (1) CZ300249B6 (pt)
DE (1) DE69942123D1 (pt)
HK (1) HK1040253B (pt)
HU (1) HUP0103851A3 (pt)
ID (1) ID28494A (pt)
IL (2) IL141415A0 (pt)
MY (1) MY125150A (pt)
NO (1) NO328523B1 (pt)
NZ (1) NZ510509A (pt)
PL (1) PL203227B1 (pt)
RU (1) RU2223967C2 (pt)
TR (1) TR200100766T2 (pt)
TW (1) TW576839B (pt)
WO (1) WO2000015658A1 (pt)
ZA (1) ZA200101861B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
IL144032A0 (en) * 1999-01-13 2002-04-21 Genentech Inc Serine protease inhibitors
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
CA2388408A1 (en) * 1999-10-01 2001-04-12 Chugai Seiyaku Kabushiki Kaisha Prevention and treatment of diseases associated with blood coagulation
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
EP1162194A1 (en) * 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
MXPA03009130A (es) 2000-10-20 2004-02-26 Biocryst Pharm Inc Compuestos de biarilo que funcionan como inhibidores de proteasa serina.
EE200300192A (et) 2000-12-06 2003-08-15 Aventis Pharma Deutschland Gmbh Guanidiini ja amidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline preparaatning eelravim
WO2002062829A1 (fr) * 2001-02-02 2002-08-15 Chugai Seiyaku Kabushiki Kaisha Derives de peptide
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7604932B2 (en) * 2002-11-13 2009-10-20 Haematologic Technologies, Inc. Assay for tissue factor in a sample
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479677A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1479680A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
EP1628954A2 (en) 2003-05-20 2006-03-01 Genentech, Inc. Acylsulfamide inhibitors of factor viia
EP1626966A1 (en) 2003-05-20 2006-02-22 Genentech, Inc. Benzofuran inhibitors of factor viia
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
WO2008107362A2 (en) * 2007-03-07 2008-09-12 Novo Nordisk Health Care Ag Stabiliser and inhibitors of factor vii
EP2176223B1 (en) 2007-07-10 2013-01-23 Sanofi Malonamide derivatives with antithrombotic activity
EP2235042A1 (en) * 2008-01-23 2010-10-06 Novo Nordisk Health Care AG New blood coagulation factor inhibitors
TR201807926T4 (tr) 2011-02-04 2018-06-21 Octapharma Ag Koagülasyon faktörlerinin çökeltme yoluyla etkisizleştirilmesine/çıkarılmasına yönelik usul.
US20220064216A1 (en) * 2018-09-11 2022-03-03 Anbition S.R.L. Peptides and medical uses thereof
CA3112175A1 (en) * 2018-09-11 2020-03-19 Anbition S.R.L. Peptides and medical uses thereof
BR112021026410A2 (pt) 2019-07-01 2022-02-08 Tonix Pharma Ltd Anticorpos anti-cd154 e usos dos mesmos
MX2023008055A (es) 2021-01-06 2023-08-22 Tonix Pharma Ltd Métodos para inducir tolerancia inmune con anticuerpos anti-cd154 modificados.
GB202209228D0 (en) * 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
EP0391999A4 (en) * 1988-09-23 1991-03-13 Corvas, Inc. Peptidyl inhibitors of the initiation of coagulation
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
US5190919A (en) * 1989-11-13 1993-03-02 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DK0703923T3 (da) * 1993-06-18 1999-06-21 Nycomed Imaging As Faktor VII afledte peptider
US5849510A (en) * 1994-04-26 1998-12-15 Selectide Corporation Factor Xa inhibitors
NZ284977A (en) * 1994-04-26 1998-09-24 Selectide Corp Factor xa enzyme inhibitor
US5837684A (en) * 1995-06-07 1998-11-17 Nycomed Imaging As Peptides
DK0892780T3 (da) * 1996-02-22 2003-03-03 Bristol Myers Squibb Pharma Co m-Amidinophenylanaloger som faktor Xa-inhibitorer
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors

Also Published As

Publication number Publication date
US6287794B1 (en) 2001-09-11
IL141415A (en) 2006-09-05
ZA200101861B (en) 2001-10-22
TR200100766T2 (tr) 2001-10-22
JP2002524571A (ja) 2002-08-06
NZ510509A (en) 2002-09-27
MY125150A (en) 2006-07-31
HK1040253A1 (en) 2002-05-31
NO20011293D0 (no) 2001-03-14
CA2344048A1 (en) 2000-03-23
WO2000015658A1 (en) 2000-03-23
NO20011293L (no) 2001-05-04
IL141415A0 (en) 2002-03-10
PL346781A1 (en) 2002-02-25
EP1114061A1 (en) 2001-07-11
AR027814A1 (es) 2003-04-16
ID28494A (id) 2001-05-31
HK1040253B (zh) 2005-09-02
PL203227B1 (pl) 2009-09-30
CN1318069A (zh) 2001-10-17
TW576839B (en) 2004-02-21
CZ2001914A3 (en) 2001-06-13
AU760580B2 (en) 2003-05-15
RU2223967C2 (ru) 2004-02-20
CN1203087C (zh) 2005-05-25
KR100665490B1 (ko) 2007-01-10
ATE460424T1 (de) 2010-03-15
AU5972399A (en) 2000-04-03
EP1114061B1 (en) 2010-03-10
DE69942123D1 (de) 2010-04-22
NO328523B1 (no) 2010-03-08
EP0987274A1 (en) 2000-03-22
HUP0103851A2 (hu) 2002-04-29
CZ300249B6 (cs) 2009-04-01
JP4537581B2 (ja) 2010-09-01
HUP0103851A3 (en) 2002-05-28
KR20010075130A (ko) 2001-08-09

Similar Documents

Publication Publication Date Title
BR9913742A (pt) Inibidores de fator viia
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
UY27404A1 (es) Composición cristalina que contiene escitalopram
TR199903193T1 (xx) Mukozaya uygulanmak �zere farmas�tik kompozisyon.
IT1295694B1 (it) Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
DK0670310T3 (da) Bisulfitaddukt af argininaldehyder egnet som thrombininhibitorer og som antikoagulanter
PT799209E (pt) Novas sulfonamidas
DK1079807T3 (da) Anvendelse af præparater til tilförsel af antiseptiske midler og/eller midler, som fremmer heling af sår, til de nedre luftveje
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
DE69318503D1 (de) Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
BR9813651A (pt) Compostos antipicornavirais e métodos para o seu uso e preparação
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
ES2018478B3 (es) Un sistema para preparar una composicion desensibilizante dental.
HUP9901586A2 (hu) Antifungális szert és acetátpuffert tartalmazó készítmények és alkalmazásuk
TR200100239T2 (tr) Matris metaloproteinazların önlenmesinde kullanılan trisiklik sülfonamitler ve türevleri.
DK0710108T3 (da) Flydende, farmaceutisk præparat til oral anvendelse indeholdende 2-(4-isobutylphenyl)-propionsyre
BR0115518A (pt) Kit de repinotan
BR9706386A (pt) Antagonistas do receptor de vitronectina, sua preparação e seu us0
ES2172600T3 (es) Composicion farmaceutica que comprende lamotrigina.
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
BR0210207A (pt) Derivados de pirrolidina como inibidores do fator xa
BR0012475A (pt) Compostos de titânio, preparação e utilização dos mesmos
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
BRPI0014878B8 (pt) composição farmacêutica contendo ciclosonida para aplicação à mucosa

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements